Pfizer To Buy King Pharma For $3.6 billion In Order to Strengthen Pain Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer will gain access to King's specialized portfolio of medications for acute, severe pain and to Remoxy, which could catapult the Big Pharma into the controversial but promising field of tamper-resistant opioid medications.